Indaptus Therapeutics to Present at the LD Micro Main Event XVI
27 September 2023 - 10:00PM
Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that
Jeffrey A. Meckler, Chief Executive Officer, will present a
corporate overview at the LD Micro Main Event XVI. The conference
is being held on October 3 – 5, 2023 at the Luxe Sunset Boulevard
Hotel in Los Angeles.
Event: |
|
LD Micro Main
Event XVI |
Presentation Date: |
|
Tuesday, October 3 |
Time: |
|
12:30pm PT (Track 3) |
Webcast Link: |
|
https://me23.sequireevents.com/ |
A live webcast of the presentation can be
accessed on the investors section of the Indaptus website
at https://indaptusrx.com/investors/events-presentations/.
A replay will be available through the same link following the
conference.
Mr. Meckler will be available for one-on-one
meetings throughout the conference.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of
immunotherapy advances. The Company’s novel approach is based on
the hypothesis that efficient activation of both innate and
adaptive immune cells and pathways and associated anti-tumor and
anti-viral immune responses will require a multi-targeted package
of immune system-activating signals that can be administered safely
intravenously (i.v.). Indaptus’ patented technology is composed of
single strains of attenuated and killed, non-pathogenic,
Gram-negative bacteria producing a multiple Toll-like receptor
(TLR), Nucleotide oligomerization domain (Nod)-like receptor (NLR)
and Stimulator of interferon genes (STING) agonist Decoy platform.
The products are designed to have reduced i.v. toxicity, but
largely uncompromised ability to prime or activate many of the
cells and pathways of innate and adaptive immunity. Decoy products
represent an antigen-agnostic technology that have produced
single-agent activity against metastatic pancreatic and orthotopic
colorectal carcinomas, single agent eradication of established
antigen-expressing breast carcinoma, as well as
combination-mediated eradication of established hepatocellular
carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical
models, including syngeneic mouse tumors and human tumor
xenografts. In pre-clinical studies tumor eradication was observed
with Decoy products in combination with anti-PD-1 checkpoint
therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory
drug, or an approved, targeted antibody. Combination-based tumor
eradication in pre-clinical models produced innate and adaptive
immunological memory, involved activation of both innate and
adaptive immune cells, and was associated with induction of innate
and adaptive immune pathways in tumors after only one i.v. dose of
Decoy product, with associated “cold” to “hot” tumor inflammation
signature transition. IND-enabling, nonclinical toxicology studies
demonstrated safe i.v. administration without sustained induction
of hallmark biomarkers of cytokine release syndromes, possibly due
to passive targeting to liver, spleen, and tumor, followed by rapid
elimination of the product. Indaptus’ Decoy products have also
produced significant single agent activity against chronic
hepatitis B virus (HBV) and chronic human immunodeficiency virus
(HIV) infections in pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking statements with the
meaning of the Private Securities Litigation Reform Act. These
include statements regarding management’s expectations, beliefs and
intentions regarding, among other things: our expectations and
plans regarding Phase 1 clinical trial of Decoy20, including the
timing and design thereof, and our expectations regarding the
recommended Phase 2 doses for subsequent multi-dosing and
combination studies and related timing; the anticipated effects of
our product candidates, including Decoy20; the plans and objectives
of management for future operations; our research and development
activities and costs; the sufficiency of our cash, cash equivalents
and marketable securities to fund our going activities and our cash
management strategy; and our assessment of financing options to
support our corporate strategy. Forward-looking statements can be
identified by the use of forward-looking words such as “believe”,
“expect”, “intend”, “plan”, “may”, “should”, “could”, “might”,
“seek”, “target”, “will”, “project”, “forecast”, “continue” or
“anticipate” or their negatives or variations of these words or
other comparable words or by the fact that these statements do not
relate strictly to historical matters. Because forward-looking
statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that
could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to the
following: our limited operating history; conditions and events
that raise substantial doubt regarding our ability to continue as
going concern; the need for, and our ability to raise, additional
capital given our lack of current cash flow; our clinical and
preclinical development, which involves a lengthy and expensive
process with an uncertain outcome; our incurrence of significant
research and development expenses and other operating expenses,
which may make it difficult for us to attain profitability; our
pursuit of a limited number of research programs, product
candidates and specific indications and failure to capitalize on
product candidates or indications that may be more profitable or
have a greater likelihood of success; our ability to obtain and
maintain regulatory approval of any product candidate; the market
acceptance of our product candidates; our reliance on third parties
to conduct our preclinical studies and clinical trials and perform
other tasks; our reliance on third parties for the manufacture of
our product candidates during clinical development; our ability to
successfully commercialize Decoy20 or any future product
candidates; our ability to obtain or maintain coverage and adequate
reimbursement for our products; the impact of legislation and
healthcare reform measures on our ability to obtain marketing
approval for and commercialize Decoy20 and any future product
candidates; product candidates of our competitors that may be
approved faster, marketed more effectively, and better tolerated
than our product candidates; our ability to adequately protect our
proprietary or licensed technology in the marketplace; the impact
of, and costs of complying with healthcare laws and regulations,
and our failure to comply with such laws and regulations;
information technology system failures, cyberattacks or
deficiencies in our cybersecurity; and unfavorable global economic
conditions. These and other important factors discussed under the
caption “Risk Factors” included in our Quarterly Report on Form
10-Q for the quarter ended June 30, 2023 filed with the SEC on
August 14, 2023, our most recent Annual Report on Form 10-K filed
with the SEC on March 17, 2023, and our other filings with the SEC,
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. All forward-looking statements speak only as of the date
of this press release and are expressly qualified in their entirety
by the cautionary statements included in this press release. We
undertake no obligation to update or revise forward-looking
statements to reflect events or circumstances that arise after the
date made or to reflect the occurrence of unanticipated events,
except as required by applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:CORE IRLouie
Tomalouie@coreir.com
Media Contact:CORE IRJules
Abrahamjulesa@coreir.com917-885-7378
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From May 2024 to Jun 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2023 to Jun 2024